期刊文献+

Crystal Structure of a Cu(Ⅱ) Coordination Polymer: [Cu(IP)(TBZH)]_(2n) (TBZH = Thiabendazole, IP = Isophthalic Acid)

Crystal Structure of a Cu(Ⅱ) Coordination Polymer: [Cu(IP)(TBZH)]_(2n) (TBZH = Thiabendazole, IP = Isophthalic Acid)
在线阅读 下载PDF
导出
摘要 The structure of a copper(Ⅱ) polymer, [Cu(IP)(TBZH)]2n 1 (TBZH = thiabendazole, IP = isophthalic acid), has been determined by X-ray crystallography and characterized by elemental analysis, IR spectrum and thermogravimetric analysis. It crystallizes in the monoclinic system, space group P21/n with a = 11.76, b = 10.41, c = 14.08A^°, β = 104.80°, V= 1666.0(3)A^°^3, Z = 4, Mr= 428.90, Dc= 1.710 g/cm^3, F(000) = 868,μ = 1.468 mm^-1 and S = 1.001. The 2-D layered gridding architecture of 1 is constructed from isophthalic acid and binuclear copper atoms. Hydrogen bonds and aryl ring π-π stacking interactions in 1 contribute to a supramolecular structure. The structure of a copper(Ⅱ) polymer, [Cu(IP)(TBZH)]2n 1 (TBZH = thiabendazole, IP = isophthalic acid), has been determined by X-ray crystallography and characterized by elemental analysis, IR spectrum and thermogravimetric analysis. It crystallizes in the monoclinic system, space group P21/n with a = 11.76, b = 10.41, c = 14.08A^°, β = 104.80°, V= 1666.0(3)A^°^3, Z = 4, Mr= 428.90, Dc= 1.710 g/cm^3, F(000) = 868,μ = 1.468 mm^-1 and S = 1.001. The 2-D layered gridding architecture of 1 is constructed from isophthalic acid and binuclear copper atoms. Hydrogen bonds and aryl ring π-π stacking interactions in 1 contribute to a supramolecular structure.
出处 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 2009年第4期434-438,共5页 结构化学(英文)
基金 supported by Siping Sci-tech Development Planning Project (No. 2005012)
关键词 THIABENDAZOLE copper(Ⅱ) complex single-crystal structure thiabendazole, copper(Ⅱ) complex, single-crystal structure
  • 相关文献

参考文献21

  • 1Kaniskan, N.; Ogretir, C. J. Mol. Struct. 2002, 584, 45-52.
  • 2Devereux, M.; McCann, M.; Shea, D. O,; Kelly, R.; Egan, D.; Deegan, C.; McKee, V. J. lnorg. Biochem. 2004., 98, 1023-1031.
  • 3James, D. M.; Gilles, H. M. (Eds.). Human Antiparasitic Drugs: Pharmacology and Usage, John Wiley & Sons, New York 1996, 206.
  • 4Delescluse, C.; Piechock, M. P., Ledirac, N.; Hines, R. H.; Li, R.; Gidrol, X.; Rahmani, R. Biochem. Pharmacol. 2001, 61,399-407.
  • 5Devereux, M.; Shea, D. O; Kellett, A.; McCann, M.; Walsh, M.; Egan, D.; Deegan, C.; Kedziora, K.; Rosair, G.; MUller-Bun,z, H. J.
  • 6Inorg. Biochem. 2007, 101,881-892.
  • 7Higashi, T. Program for Absorption Correction. Rigaku Corporation, Tokyo, Japan 1995.
  • 8Sheldrick, G. M. SHELXS-97, Program for Automatic Solution of Crystal Structure, University of Gottingen, Germany 1997.
  • 9Sheldrick, G. M. SHELXS-97 Program for Crystal Structure Refinement, University of GOttingen, Germany 1997.
  • 10Farrugia, L. J.; Wing, X. A. Windows Program for Crystal Structure Analysis, University of Glasgow, Glasgow, UK 1988.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部